Hopp til innhold

Get alerts of updates about «Health Technology Assessment of medicines used for multiple sclerosis»

How often would you like to receive alerts from fhi.no? (This affects all your alerts)
Do you also want alerts about:

The email address you register will only be used to send you these alerts. You can cancel your alerts and delete your email address at any time by following the link in the alerts you receive.
Read more about the privacy policy for fhi.no

You have subscribed to alerts about:

  • Health Technology Assessment of medicines used for multiple sclerosis

Project

Health Technology Assessment of medicines used for multiple sclerosis - project description

Published

The present Health Technology Assessment (HTA) have added two new medicines for the indication and removed a group of medicines (interferons) due to low priority use. We also included one medicine without marketing authorisation, rituximab (a drug with marketing authorisation for rheumatoid arthritis, B cell non-Hodgkin's lymphomas and a few types of cancer), which is used off-label in MS-patients.


Summary

Multiple sclerosis (MS) is a chronic, inflammatory disease affecting the central nervous system (CNS). The symptoms depend on the location of the lesions in the CNS. The prevalence rate for multiple sclerosis in Norway is among the highest reported worldwide. This disease, which usually starts around the age of 30 (range 20-40), most commonly has a relapsing-remitting course in about half the patients, followed by a secondary progressive phase. Most patients experience increasing disability involving motor, sensory, visual, and bowel and bladder systems. The medicines used today in patients with signs or symptoms of inflammation are disease-modifying drugs. In 2016 the NIPH conducted a Health Technology Assessment (HTA), including a network meta-analyses, on 11 different medicines

(https://nyemetoder.no/metoder/multippel-sklerose-ms-fullstendig-metodevurdering).

The present Health Technology Assessment (HTA) have added two new medicines for the indication and removed a group of medicines (interferons) due to low priority use. We also included one medicine without marketing authorisation, rituximab (a drug with marketing authorisation for rheumatoid arthritis, B cell non-Hodgins's lymphomas and a few types of cancer), which is used off-label in MS-patients. We aim at examining the relative effect, safety and cost-effectiveness of these medicines used for multiple sclerosis in Norway. The report will also assess the legal and ethical implications using rituximab off-label.

Project number

ID2018_004

Duration

1 år

Start

05.2018

End

05.2019

Status

Active

Principal institution

Project owner/ Project manager

Folkehelseinstituttet

External participants

Effect and safety: Lars Bø, MD, Helse Bergen, Trygve Holmøy, MD, Ahus/UiO, Elisabeth Gulowsen Celius, MD, OUS/UiO, Rune Midgard, MD, Molde og Ålesund. Law and ethics: To be decided